The potent long-acting antibody (LAAB) combination originally developed by Vanderbilt University reveals positive high-level results from the TACKLE Phase III COVID-19 treatment trial. AstraZeneca's AZD7442 achieved a statistically significant reduction in severe COVID-19 or death compared to placebo in non-hospitalized patients with mild-to-moderate symptomatic COVID-19. While not as convenient to administer as an oral antiviral this therapy would introduce yet another important therapeutic to help care for COVID-19 patients. TrialSite suggests the transition from pandemic to the endemic stage of COVID-19 is well on its way.
TrialSite reported early on the original discovery by Vanderbilt then the AstraZeneca licensing deal. AstraZeneca secured $486 million from the U.S. government to help develop these experimental therapies. The company sponsored three Phase 3 clinical trials representing the quest to investigate whether A) it was possible to introduce to the market a therapy that serves as both Pre-Exposure Prophylaxis (PrEP) and/or B) Post-Exposure Prophylaxis (PeP) protecting people from COVID-19 and 3) the TACKLE study.
A total of 90% of participants en...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).